SCHEMBL25213787

SCHEMBL25213787

CC(=O)N1CCC(C(=O)N(O)Cc2ccc(Nc3ccc(C(C)(C)C)cc3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.44
▸ MAPK1 P28482 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ EPHX2 P34913 2/20 0.41
▸ PTPRB P23467 1/20 0.40
▸ PTPN11 Q06124 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ HDAC3 O15379 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25189127 0.89 RORC (0.42) TRPV1MAPTEPHX2PTPRBPTPN11
SCHEMBL25187989 0.89 HDAC3 (0.44) TRPV1EPHX2RORCHDAC3HDAC8
SCHEMBL25190745 0.86 GAA (0.47) EPHX2ALDH1A1RORCCNR2HDAC3
SCHEMBL25190807 0.81 HDAC3 (0.39) TRPV1SMN1; SMN2RORCHDAC3HDAC8
SCHEMBL25200167 0.80 MAPT (0.44) TRPV1MAPK1USP2TP53MAPT
SCHEMBL25183896 0.78 NR1H4 (0.46) TRPV1MAPTEPHX2SMN1; SMN2
SCHEMBL25204881 0.78 RORC (0.36) TRPV1PTPRBPTPN11RORC
SCHEMBL25193063 0.75 ALOX15 (0.48) TRPV1MAPTHSD17B10EPHX2ALDH1A1
SCHEMBL25190146 0.75 EPHX2 (0.46) EPHX2RORCHDAC3HDAC8HDAC6
SCHEMBL25194563 0.73 RIPK1 (0.44) MAPTEPHX2SMN1; SMN2RORCHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 — — CN disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
CN-115151252-A Iron death inhibitors diarylamine para-acetamides 维泰瑞隆有限公司 2022-10-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES AIFM2, FECH, GPX4 TRPV1 429/4885MAPK1 2726/4885USP2 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback